WO2000075179A1 - Chromatographic determination of p-glycoprotein reactive ligands - Google Patents
Chromatographic determination of p-glycoprotein reactive ligands Download PDFInfo
- Publication number
- WO2000075179A1 WO2000075179A1 PCT/US2000/015820 US0015820W WO0075179A1 WO 2000075179 A1 WO2000075179 A1 WO 2000075179A1 US 0015820 W US0015820 W US 0015820W WO 0075179 A1 WO0075179 A1 WO 0075179A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pgp
- vbl
- chromatographic
- immobilized
- binding
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
Definitions
- This invention relates to immobilization of transporters on a support in a liquid chromatographic system.
- BP-SPs immobilized biopolymer-based LC stationary phases
- PGP P-glycoprotein
- MDR multidrug resistance
- the MDR1 genes encode the PGP that is involved in the MDR phenotype.
- a breast tumor is two times more likely to express MDR1/PGP if it has been exposed to cytotoxic chemotherapy and almost three times more likely to be resistant to adriamycin in vitro if it expresses MDR1/PGP.
- the invention provides for liquid chromatographic stationary phases to which are immobilized transporters, especially P-glycoproteins. These stationary phases are useful for identifying compounds by a continuous liquid chromatographic process which provides for the characterization, isolation and/or identification of compounds that specifically bind to the immobilized transporter. Thereby, the invention provides continuous on-line processes for identifying and isolating agents that bind to transporters, especially p- glycoproteins.
- the present invention provides substrate systems and methods for continuous on-line evaluation, identification and isolation of compounds which bind to PGP.
- Description of the Invention It is the purpose of this invention to provide means for immobilization of membrane transporters in order to study interactions of compounds therewith.
- the fundamental processes of drug action, absorption, distribution and receptor activation, are dynamic in nature and have much in common with the basic mechanisms involved in chromatographic distribution. Indeed, the same basic intermolecular interactions (hydrophobic, electrostatic and hydrogen bonding) determine the behavior of chemical compounds in both biological and chromatographic environments.
- receptors and transporters play an important role in drug activity and are key targets in combinatorial screens, they have not been included in LC systems.
- receptors on supports comprising the steps of:
- the present invention is exemplified herein using a PGP-based LC stationary phase for the study of drug-PGP interactions.
- the method was assessed in studies of the binding affinity of vinblastine, verapamil and cyclosporin A on PGP. Based thereon, it is anticipated that the present invention should be suitable for study of other ligand interactions with PGP in a dynamic manner.
- the PGP -based stationary phase can be prepared by embedding PGP in a phospholipid monolayer of an immobilized artificial membrane (AIM) HPLC stationary phase, creating the PGP-IAM.
- AIM immobilized artificial membrane
- PGP can be reconstituted into the phospholipid layer of liposomes that are immobilized on Superdex 200 gel beads by using freeze-thawing methods (PGPLIP).
- PGPLIP freeze-thawing methods
- the PGP-IAM was used to determine the PGP binding affinities of the vinblastine, cyclosporin A and verapamil. The binding affinities were assessed using frontal chromatographic techniques. The rank order of the calculated K d values, i.e., highest affinity to lowest affinity, are consistent with previously reported values.
- the PGP-IAM was stable, reproducible and deemed a useful addition to the art relating to G-ligand interactions and provides means for the use of rapid on-line screening of new agents for the treatment of MDR1/PGP resistant tumors.
- Figure 1 shows elution profile of [ 3 H]VB[lnm] in frontal chromatography based on the PGP IAM column (0.5 X 0.8 cm) in the absence and in the presence of doxorubicin (200 nm) (profile B) in the mobile phase.
- Tris -Hcl buffer [50 mm, pH 7.4], flow rate 0.4 ml/min.
- Figure 2 is a frontal analysis of interaction of PGP with verapamil on an immobilized PGP-IAM column (0.5 X 0.8 cm).
- Running buffer is 50 mM Tris-HCl, pH 7.4 at a flow rate of 0.5 ml/min.
- Figure 3 is a nonlinear regression analysis of verapamil interaction with PGP-IAM.
- the data is from frontal analysis measurements.
- Figure 4 shows zonal affinity chromatographic profiles of 100 ⁇ l of 23.5 nM [ 3 H] verapamil at a flow rate of 0.5 ml/min with 50 mM Tris-HCl, pH 7.4 buffer, (1) was from PGP-negative-IAM column, (2) was from IAM particles column, and (3) was from PGP-IAM column.
- Figure 5 is a frontal affinity analysis of 1.0 nM [ 3 H] cyclosporine A was in the sample alone, (B) 50 nM cold vinblastine was supplemented in the sample, (C) 3 mM ATP was in the sample and running buffer, (D) 100 nM cold vinblastine was added in the sample.
- the running buffer was 50 mM Tris-NCl, pH 7.4.
- Figure 6 is a frontal affinity chromatographic analysis of 1 nM [ 3 H] vinblastine with PGP-IAM on a column of 0.5 X 0.8 cm at a flow rate of 0.5 ml/min (A). It was obtained with 1.0 nM [ 3 H] vinblastine only (B). 1.0 nM [ 3 H] vinblastine supplemented with 3 mM ATP.
- the running buffer for both (A) and (B) was 50 mM Tris-IICl, pH 7.4 with 1.6% ethanol.
- the cultured cells MDA436/LCC6MDR1 ( 20 x 106 cells) were harvested in 30 ml of PBS saline and homogenized for 20 sec with a Brinkmann Polytron homogenizer. The homogenates were centrifuged at 35,000 x g for 10 min and the pellets were suspended in 4 ml solubilization solution (50 mM Tris-HCl, pH 7.4, 250 mM NaCl, 0.5% CHAPS, 2 mM DTT, 5% glycerol) and stirred for 1 hr at O° C. Two hundred (200) mg of dried IAM particles was suspended in 4 ml receptor-detergent solution and stirred for 1 hour at 4 C.
- solubilization solution 50 mM Tris-HCl, pH 7.4, 250 mM NaCl, 0.5% CHAPS, 2 mM DTT, 5% glycerol
- the mixture was dialyzed against dialysis buffer (150 mM NaCl, 10 mM Tris-HCl buffer, pH 7.4, 1 mM EDTA) for 72 hours at 4° C.
- the obtained PGP-IAM particles were washed with the buffer by centrifugation and packed in a glass column (id 0.5 cm).
- the cultured cells MDA436/LCC6MDR1 (20 x 10 6 cells) were harvested in 20 ml of PBS saline and homogenized for 20 sec with a Brinkmann Polytron homogenizer. The homogenates were centrifuged at 35,000 x g for 10 min and the supernatant was discarded.
- the pellets were suspended in 4 ml solubilization solution [50 mM Tris-HCl, pH 7.5 containing 1.4% octyl -D-glucopyranoside, 20% glycerol, 1 mM Dithiothreitiol, 1 mM benzamidine and 0.4% phospholipid: E.coli bulk phospholipid: PC:PS:Cholesterol (60:17.5:10:12.5)] by stirring at 0° C for 40 minutes. Nonsoluble material was removed by centrifugation.
- the supernatant was applied on to a Sephadex G50 column which equilibrated with elution buffer (150 mM NaCl, 10 mM TrisHCl, 1 mM EDTA, 1 mM Benzamidine).
- elution buffer 150 mM NaCl, 10 mM TrisHCl, 1 mM EDTA, 1 mM Benzamidine.
- the liposome fractions were collected and concentrated to 1 ml.
- the concentrated liposome solution was mixed with 50 mg dried Superdex 200 and kept in room temperature for 2 hours.
- the mixture of liposome and Superdex 200 was frozen at -75 C for 10 min and then thawed at 25 C for 10 min and the freeze-thaw cycle was repeated.
- the non-immobilized liposomes were removed by centrifugation and the resulting PGP-Superdex gel beads were packed in a LC column. Chromatographic analysis of binding affinity of 3H VBL at PGP
- the PGP-IAM column or PGP-Superdex 200 column was washed with buffer (150 mM NaCl, 10 mM Tris-HCl buffer, pH 7.4, 1 mM EDTA). The column was placed in a standard HPLC system. 10-40 ml of 3H VBL with different concentrations in buffer or 1 nM 3H-VBL plus 200 nM ADR in buffer were applied onto the columns at 0.4 ml/min. An on-line flow scintillation detector monitored the elution profile. Binchoninic Acid fBCA) Protein Assay
- the PGP-IAM and PGP-Superdex 200 packing materials were collected and the supernatants were removed.
- the samples were diluted with 0.1 N of NAOH to 2 ml.
- a protein standard (0.2-25 g protein in 50 1) was prepared with Albumin standard (Pierce) and 20 ml of reagent A mixed with 0.4 ml of reagent B.
- the standards and samples (50 1 each) were added to triplicate wells in a plate. 200 1 of BCA reagents (A+B) (Pierce) was added in each well.
- the plate was incubated for 2h at room temperature and read in a spectrophotometer at 570 nm using the Softmax program for calculation of the protein amount.
- the protein assay showed that for one milliliter of bed volume, about 170 mg proteins were immobilized on IAM column and about 10 mg proteins were immobilized on Superdex 200 column.
- 3H-VBL was retarded on a PGP-IAM column (0.5 x 0.8 cm) and the retention volume was 13.3 ml at the concentration of 1 nM (profile A in Fig 6) at flow rate: 0.4 ml/min.
- the retention volumes of 3H-VBL at the different concentration in frontal chromatography were used to calculate the Kd value.
- the obtained Kd value for 3H-VBL determined in this technique is 19 ⁇ 20 nM; that is consistent with the reported value, 36 ⁇ 55 nM.
- EXAMPLE 2 On-line screening of complex mixtures for PGP substrates Step 1: Initial Chromatographic Screen: The Initial Chromatographic Screen has been described above. Step 2: Secondary Chromatographic Screen:
- the primary fractions isolated in the Initial Chromatographic Screen and screened are concentrated under reduced pressure to a volume of approximately
- the primary fraction is injected on the PGP-SP column and the switching valve is be set to direct the flow from the PGP-SP column to the storage container. This configuration of the system is maintained until the elution volume ⁇ or k' ⁇ of the least retained marker PGP-substrate ⁇ i.e., VBL, TAX, or
- Chromato raphic Step B After the k' of the least retained marker PGP-substrate has been reached, the switching valve is rotated and the flow from the PGP-SP column is directed onto the C18 column for the analytical separation of the compounds eluted from the PGP-SP.
- the mobile phases employed on the PGP-SP primarily consists of aqueous buffers it is assumed that the compounds will not elute from the C18 under these conditions and will concentrate at the top of the analytical column.
- the gradient elution program elutes the compounds from the Cl 8 column and into the pre-MSD splitting valve. A portion of the compounds eluted from the C18 column is directed through the splitter to collection tubes placed in an automatic fraction collector and stored for use. The remaining portion of the compound is directed to the HP 1100 MSD and the corresponding mass spectrum obtained.
- the automatic fraction collector is controlled by a signal from the MSD. When the slope of the total ion current detected by the MSD changes in a positive direction, the automatic fraction collector moves from waste to the next available collection tube and when the ion current returns to a preset level, the automatic fraction collector returns to waste.
- Step 3 Additional Chromatographic Screens
- the active fractions can be chromatographed again on another PGP-SP LC/MS system.
- the C18-SP is be replaced by a cyanopropyl-SP.
- Alternative approaches include other chromatographic phases such as the aminopropyl or phenyl bonded SPs.
- an immobilized HSA-SP can also be employed in order to eliminate compounds that display extensive protein binding and, therefore, limited bioavailability.
- the fractions can be collected as described above and assayed in accord with the teachings herein. Steps 1 and 2 - Throughput:
- Preparation of mg or greater quantities of active lead compounds A flow-chart for the isolation of the active compounds can be developed from the chromatographic experiments. The biological extracts containing these compounds can be processed using a flow-chart. For illustrative purposes, a sample flow chart is presented: A. Initial Chromatographic Screen: Take the 3rd fraction after the VBL retention volume.
- the Initial Chromatographic Screen and larger format columns, i.e., a standard 150 mm x 4.1 mm ID column or greater, can be employed in the Second Chromatographic Screen. Since the initial process has the capacity to process kg quantities of botanical extracts, mg and greater quantities of active lead candidates can be prepared. Thus, enough compound can be isolated to fully characterize the molecular structure of an active lead compound and to fully characterize the in vitro activity of this compound. If the compound proves promising, larger quantities could also be produced for preliminary in vivo studies if an adequate chemical synthesis has not been developed using methods of chromatographic isolation of the active compounds from complex biological matrices known in the art.
- the PGP-SP can be used to characterize ligand- biopolymer interactions, including the direct determination of binding affinities; the identification of specific sites at which a ligand binds; elucidation of ligand- ligand binding interactions including competitive and allosteric interactions.
- k' is directly proportional to its binding affinity to PGP.
- the magnitude and direction of the resulting changes in k' can be used to determine if the "displacer” binds at the same site(s) as the marker PGP-substrates and to indicate if co-operative ⁇ k' increases ⁇ , anti-co-operative ⁇ k' decreases ⁇ and non-co-operative ⁇ k' decrease ⁇ interactions occur between the "solute" and "displacer".
- the relationship between the k' of the solute and the mobile phase concentration of the displacer is expressed by the equation 1 :
- VM void volume of the column
- K2 and K3 equilibrium constants for the binding of the displacer and solute, respectively
- mL moles of the solute bound to the stationary phase
- [D] concentration of the displacer in the mobile phase
- X residual k' resulting from binding at sites unaffected by the displacer.
- K2 the binding affinity constant for the displacer
- the development of the QSRR analysis of the data set can be run according to the procedures previously published.
- the lead PGP-drugs can be chromatographed on the PGP-SP under the same experimental conditions and their k's determined.
- the molecular structures of the compounds will also be constructed using Insitell 95.0 running on a Silicon Graphics Indy workstation and the molecular descriptors of the structures calculated ⁇ i.e., hydrophobicity, molecular volume, electronic distribution, molecular geometries, etc. ⁇ using Tsar V2.41 , Mopac V6 and Insitell 95.0 software and the Connolly surfaces will be calculated using MOLCAD ⁇ Tripos ⁇ software all running on the same workstation.
- the k' s of the lead PGP-drugs can be correlated to their molecular descriptors using the multivariate regression analysis program in Tsar V2.41.
- the simplest possible relationship between the descriptors can be established and the predictive power of the model determined by "leave-one-out" cross- validation.
- the pharmacophores can be developed as previously described in the art.
- pharmacophores can be built using Apex-3D 95.0 software run on the Silicon Graphic Indy workstation.
- the pharmacophores can be constructed using all of the compounds in the set with a match superimposition greater than 0.7.
- 3D-QSAR equations can be derived with the site radius initially set at 1.3, the occupancy at 5, the sensitivity at 2.5 and the randomization at 500.
- the data from the chromatographic, QSAR and pharmacophore modeling can provide direction to the combinatorial synthesis of new compounds to bring effective therapeutic agents to clinical trial.
- the knowledge gained using methods of the invention can be used to produce additional stationary phases with different biochemical targets such as Protein Kinase C.
- the screening of extracts and combinatorial pools can be expanded to other therapeutic areas.
- the supports with many different moieties that bind to ligands may be exposed to drugs or inhibitors, then to drugs followed by chromatographic evaluation of the presence of the drug by chromatographic means to determine whether the drug is present on the support.
- it is also possible to determine whether proposed inhibitors of interaction will, in fact, prevent an interaction by exposing the prepared support having the appropriate protein bound thereto to proposed inhibitors, then to the toxin or drug followed by chromatographic evaluation of the support to determine whether the toxin or drug has been prevented from binding by the inhibitor under consideration.
- the following examples provide further characterization of the PGP- stationary phase and disclose the use of frontal and zonal chromatographic techniques to investigate the binding of vinblastine, doxorubicin, verapamil and cyclosporin A to the immobilized PGP.
- the compounds were added individually to the chromatographic system with or without ATP on the running buffer.
- the compounds were also added in pairs using standard competitive chromatography procedures.
- the results of the study demonstrate that both competitive and allosteric interactions occurred during the chromatographic studies and indicate that the immobilized PGP retained its conformational mobility.
- the following materials and methods were used in these additional Examples.
- Immobilized Artificial Membrane (IAM). PC particles were obtained from Regis Chemical Co (Morton Grove, IL, USA). Glass column (HR5/5) was purchased from Amersham Pharmacia Biotech (Uppsala, Sweden). [ 3 H] vinblastine and [ 3 H]cyclosporine A were purchased from Amersham Life Science Products (Boston, MA, USA). [ 3 H]verapamil was from NENTM Life Science Products, Inc (Boston, MA, USA). Vinblastine, verapamil, doxorubicin, cyclosporin, CHAPS, glycerol, benzamidine, albumin bovine, were from Sigma Chemical Co. (St. Louis, MO, USA). GF/C glass micro fiber filters were from Whatman. Scintillation liquid (Flo-Scint V) was purchased from Packard Instruments (Meriden, CT, USA).
- the PGP-positive MDA435/LCC6 MDR1 cell line was obtained by transduction of PGP-negative expressing MDA435/LCC6 human breast cancer cells with a retroviral vector carrying MDR1 cDNA ⁇ PGP ⁇ (30).
- buffer A 50 mM Tris-HCl, pH 7.4, 50 mM NaCl, 2 ⁇ M Leupeptin, 2 ⁇ M phenylmethanesulfonyl fluoride and 4 ⁇ M pepstatin).
- the suspension of cells was homogenized for 2 x 30 s (with a cooling period inbetween) with a Brinkmann Polytron homogenizer.
- the homogenized membrane was centrifuged first at 1,000 x g for 10 min, the pellets were discarded and the supernatant was collected and centrifuged at 150,000 x g for 30 min again. The membrane pellets were collected.
- Immobilization of PGP on IAM particles The membrane pellets were resuspended in 6 ml solubilization solution (50 mM Tris-HCl, pH 7,4, 500 mM NaCl, 15 mM CHAPS, 2 mM DTT, 10 % glycerol) for 3 hours at 4°C.
- the marker ligand either [ 3 H]-vinblastine [[ 3 H]-VBL, 1.0 nM], [ ⁇ ]- verapamil [[ 3 H]-VER, 0.3 nM] or [ 3 H]cyclosporine A [[ H]-CsA, 2.0 nM] were applied to the PGP-IAM column in sample volumes of 25-50 ml.
- the solutions containing the marker ligands were supplemented with a range concentrations of either cold VBL, VER, doxorubicin or CsA.
- Elution profiles were obtained showing front and plateau regions as illustrated for [ 3 H]VER in Figure 2.
- the observed elution volume data were used for calculation of ligand dissociation constants.
- the K d values of VER and CsA were calculated by nonlinear regression, as illustrated for [ 3 H]-VER Fig. 3, using Prism (GraphPad Software) and a one-site binding (hyperbola), equation (2) below:
- Y Bmax -X / (kd + X) (2)
- X is the concentration of VER or CsA
- Y is equal to [verapamil] (V - V m ⁇ n ) or [CsA](V - V m ⁇ n ), where: V m ⁇ n is the elution volume of VER or CsA under conditions where specific interactions are completely suppressed and V is the retention volume of VER or CsA at different concentrations (0.3 - 400 ⁇ M for VER and 2.5 - 100 nM for CsA).
- V- V mm )- 1 (V m ⁇ n [P]K VBL >- 1 + (V m ⁇ n [P])-' [VBL] (4)
- I represents doxorubicin or CsA
- [P] the concentration of active receptor in the volume
- V m ⁇ n the elution volume of VBL under conditions where the specific interaction is completely suppressed
- V max is the elution volume obtained with 1.0 nM [ 3 H]VBL.
- IAM support ⁇ negative control ⁇ PGP-negative-IAM ⁇ positive control ⁇ and PGP-IAM ⁇ experimental ⁇ were separately connected on-line to a flow scintillation monitor and used in zonal chromatographic experiments.
- a mobile phase composed of Tris-HCl [50 mM, pH 7.4] was constantly pumped through the column at a flow rate of 0.5 ml/min.
- a single 100 ml injection of the marker ligand, [ 3 H]VER [23.5 nM] was injected onto the column and the radioactive signal (CPM) was recorded every six seconds.
- the chromatographic data was evaluated in 0.5 minute intervals and smoothed using the Microsoft Excel program with a 5 -point moving average.
- the filters were then washed with two portions of 5-ml ice-cold 20 mM Tris-HCl, 20 mM MgCl 2 buffer. The filters were dried, and retained radioactivity was quantitated by liquid scintillation counting. Specific binding was defined as the difference between total binding and nonspecific binding Protein Assay: The amount of membrane and the immobilized membrane were determined by bicinchoninic acid (BAC) protein assay. The sample was diluted with NaOH [0.1 M]. A protein standard (0.3 - 37.5 ⁇ g in 50 ⁇ l) was prepared with Albumin standard (Pierce, Rockford, IL).
- BAC bicinchoninic acid
- the calculated K d of VBL was 23.5 ⁇ 7.8 nM which is consistent with the previously reported values of 37.0 ⁇ 10 nM (18) and 36 ⁇ 5 nM.
- the K d value of 15.0 ⁇ 3.2 ⁇ M determined for doxorubicin was also consistent with the reported value of 31.0 ⁇ 7.3 ⁇ M.
- PGP-IAM immobilized P-glycoprotein
- the stationary phase was prepared using solubilized membranes from PGP-expressing cells.
- the donor cells were MDA435/LCC6 MDR1 , a cell line obtained by retroviral transduction of MDR1 cDNA (coding for PGP) into MDA435/LCC6 human breast cancer cells.
- a second liquid chromatographic stationary phase was prepared through the immobilization of membrane extracts from the PGP-negative MDA435/LCC6 parental cell line.
- the Kd value calculated from the frontal chromatographic studies, Table 1, appears to be the sum of VER affinity to the different VER binding sites.
- the experimental conditions used in this study could not determine if the VER and VBL sites are allosterically linked. Further studies will be effected to select specific markers for the high and low affinity VER binding sites.
- PGP is a member of the ATP-binding cassette superfamily and ATPase activity plays a role in substrate transport.
- ATPase activity plays a role in substrate transport.
- the addition of ATP to the running buffer would change the chromatographic properties of the immobilized PGP chromatographic system.
- the addition of 3 mM ATP to the running buffer increased the retention volume of [ 3 H]CsA from 7.8 ml to 17.5 ml (Table 2), produced a classical frontal chromatogram for [ 3 H]CsA ( Figure 5C) and permitted the calculation of an a k d value of 62.5 nM, Table 1.
- VBL Vinca alkaloids
- cyclosporins The results of previous studies of dissociation rates were consistent with overlapping binding sites for CsA and VBL.
- PGP PGP causes the efflux of several substrates.
- PGP is proposed to work as an "hydrophobic vacuum cleaner", binding its substrates from the inner leaflet of cell membrane and transporting them to the extracellular space, or perhaps "flipping" them to the outer leaflet. Both transport mechanisms assume a conformationally mobile molecule capable of responding to ATPase activity and substrate/inhibitor binding.
- PGP-affinity chromatography represents a promising tool for a quick and reproducible evaluation of potential PGP substrates and/or inhibitors and provides a useful probe of the transport mechanism.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001502460A JP2003501670A (en) | 1999-06-09 | 2000-06-09 | Chromatographic determination of P-glycoprotein reactive ligand |
EP00939704A EP1181311A4 (en) | 1999-06-09 | 2000-06-09 | Chromatographic determination of p-glycoprotein reactive ligands |
CA002376825A CA2376825A1 (en) | 1999-06-09 | 2000-06-09 | Chromatographic determination of p-glycoprotein reactive ligands |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15140299P | 1999-06-09 | 1999-06-09 | |
US60/151,402 | 1999-06-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000075179A1 true WO2000075179A1 (en) | 2000-12-14 |
Family
ID=22538604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/015820 WO2000075179A1 (en) | 1999-06-09 | 2000-06-09 | Chromatographic determination of p-glycoprotein reactive ligands |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1181311A4 (en) |
JP (1) | JP2003501670A (en) |
CA (1) | CA2376825A1 (en) |
WO (1) | WO2000075179A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4837306A (en) * | 1985-02-25 | 1989-06-06 | The Ontario Cancer Institute | Method for selecting hybridomas producing antibodies specific to the P-glycoprotein cell suface antigen and a cDNA clone encoding the C-terminal portion of the antigen |
-
2000
- 2000-06-09 CA CA002376825A patent/CA2376825A1/en not_active Abandoned
- 2000-06-09 JP JP2001502460A patent/JP2003501670A/en active Pending
- 2000-06-09 WO PCT/US2000/015820 patent/WO2000075179A1/en not_active Application Discontinuation
- 2000-06-09 EP EP00939704A patent/EP1181311A4/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4837306A (en) * | 1985-02-25 | 1989-06-06 | The Ontario Cancer Institute | Method for selecting hybridomas producing antibodies specific to the P-glycoprotein cell suface antigen and a cDNA clone encoding the C-terminal portion of the antigen |
Non-Patent Citations (5)
Title |
---|
GIANNI ET AL.: "Human pharmacokinetic characterization and In-vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer", JOURNAL OF CLINICAL ONCOLOGY,, vol. 15, no. 5, May 1997 (1997-05-01), pages 1906 - 1915, XP002931662 * |
KUBOTA ET AL.: "Pirarubicin might partly circumvent the P-glycoprotein-mediated drug resistance of human breast cancer tissues", ANTICANCER RESEARCH,, vol. 18, no. 2A, March 1998 (1998-03-01) - April 1998 (1998-04-01), pages 967 - 972, XP002931681 * |
See also references of EP1181311A4 * |
SPARREBOOM ET AL.: "Clinical pharmacokinetics of doxorubicin in combination with GF 120918, a potent inhibitor of MDR1-P-glycoprotein", ANTI-CANCER DRUGS,, vol. 10, no. 8, September 1999 (1999-09-01), pages 719 - 728, XP002931663 * |
ZHANG ET AL.: "Development of an immobilized P-glycoprotein stationary phase for on-line liquid chromatographic determination of binding affinities", JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL SCIENCES AND APPLICATIONS,, vol. 739, no. 1, February 2000 (2000-02-01), pages 33 - 37, XP002931661 * |
Also Published As
Publication number | Publication date |
---|---|
JP2003501670A (en) | 2003-01-14 |
EP1181311A1 (en) | 2002-02-27 |
EP1181311A4 (en) | 2004-12-15 |
CA2376825A1 (en) | 2000-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hage | Affinity chromatography: a review of clinical applications | |
Wieboldt et al. | Immunoaffinity ultrafiltration with ion spray HPLC/MS for screening small-molecule libraries | |
Moaddel et al. | Immobilized receptor-and transporter-based liquid chromatographic phases for on-line pharmacological and biochemical studies: a mini-review | |
JPH0277649A (en) | Method of analyzing free section of substance in biological fluid | |
Ohlson et al. | Fragment screening for drug leads by weak affinity chromatography (WAC-MS) | |
US20090221436A1 (en) | Process for determining target function and identifying drug leads | |
Lundahl et al. | Chromatographic approaches to liposomes, proteoliposomes and biomembrane vesicles | |
JPH08240583A (en) | Method for detecting toxic substance | |
Schriemer | Peer reviewed: biosensor alternative: frontal affinity chromatography | |
Zhang et al. | Development of an immobilized P-glycoprotein stationary phase for on-line liquid chromatographic determination of drug-binding affinities | |
JP2690164B2 (en) | Paralog affinity chromatography | |
US6410340B1 (en) | Use of an 8.4 kDa protein as an immunophilin reagent in protein binding assays for immunosuppressive drugs | |
Lecas et al. | Affinity chromatography: A powerful tool in drug discovery for investigating ligand/membrane protein interactions | |
Lu et al. | Competitive and allosteric interactions in ligand binding to P-glycoprotein as observed on an immobilized P-glycoprotein liquid chromatographic stationary phase | |
Vuckovic et al. | Automated study of ligand–receptor binding using solid-phase microextraction | |
Strandh et al. | Weak affinity chromatography | |
Moaddel et al. | Conformational mobility of immobilized proteins | |
Tong et al. | Development and thermodynamic evaluation of novel lipid raft stationary phase chromatography for screening potential antitumor agents | |
EP1181311A1 (en) | Chromatographic determination of p-glycoprotein reactive ligands | |
Kosk-Kosicka et al. | Heterogeneous halothane binding in the SR Ca2+-ATPase | |
AU8186491A (en) | Receptor assay for fk-506 | |
US6720192B1 (en) | Screening for analytes using labeled receptors | |
Ohlson et al. | Screening for transient biological interactions as applied to albumin ligands: a new concept for drug discovery | |
Bruhwyler et al. | The use of radioreceptor assays for the determination of benzodiazepines in biological samples: a review | |
Mladic et al. | Analytics for bioactivity profiling of complex mixtures with a focus on venoms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2376825 Country of ref document: CA Ref country code: JP Ref document number: 2001 502460 Kind code of ref document: A Format of ref document f/p: F Ref country code: CA Ref document number: 2376825 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000939704 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000939704 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10009344 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000939704 Country of ref document: EP |